The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis
← catalyst calendarNCT07467564 · readout in 278 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →. With Regeneron Pharmaceuticals.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
184estimated
Sites
7
Countries
Qatar, Saudi Arabia, United Arab Emirates
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-24 | actual | When the study began enrolling |
| Primary completion | 2027-05-24 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-24 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Intervention
- Drug: Dupilumab
Primary outcomes
what the primary-completion date above is the date OFProportion of Participants with Hospital Anxiety and Depression Scale Anxiety (HADS-A) Sub-scores of Less Than 8
measured Week 24
Proportion of Participants with HADS Depression (HADS-D) Sub-scores of less than 8
measured Week 24
Change from Baseline in HADS Total Score.
measured Baseline to up to Week 24
Proportion of Participants with More Than or Equal to 4-point Improvement in POEM Total Score
measured Week 24
Change from Baseline in POEM Total Score.
measured Baseline to up to Week 24
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed